Shares

7 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 12, 2024

SELL
$2.84 - $3.13 $1,056 - $1,164
-372 Reduced 75.0%
124 $0
Q4 2022

Feb 13, 2023

SELL
$1.18 - $1.76 $1,812 - $2,703
-1,536 Reduced 75.59%
496 $1,000
Q3 2022

Nov 14, 2022

BUY
$1.99 - $4.05 $1,221 - $2,486
614 Added 43.3%
2,032 $4,000
Q2 2022

Aug 11, 2022

SELL
$1.62 - $4.4 $18,660 - $50,683
-11,519 Reduced 89.04%
1,418 $4,000
Q1 2022

May 11, 2022

BUY
$3.39 - $10.51 $22,428 - $69,534
6,616 Added 104.67%
12,937 $49,000
Q4 2021

Feb 10, 2022

BUY
$9.83 - $19.21 $18,706 - $36,556
1,903 Added 43.07%
6,321 $71,000
Q3 2021

Nov 12, 2021

BUY
$14.57 - $21.86 $64,370 - $96,577
4,418 New
4,418 $77,000

Others Institutions Holding CYT

About Cyteir Therapeutics, Inc.


  • Ticker CYT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 35,413,400
  • Market Cap $107M
  • Description
  • Cyteir Therapeutics, Inc., a clinical-stage biotechnology company, develops and commercializes the next-generation of precision oncology medicines. Its lead product CYT-0851, a novel, oral, once-daily, small molecule drug candidate that is in Phase I/II clinical trial for monotherapy in solid tumors and hematologic malignancies, as well as for c...
More about CYT
Track This Portfolio

Track Jpmorgan Chase & CO Portfolio

Follow Jpmorgan Chase & CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.